Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCB101 and Pembrolizumab in Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT07136545Phase 2Recruiting
- Sponsor
- Taipei Veterans General Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HCB-101 in head and neck squamous cell carcinoma (HNSCC), sponsored by Taipei Veterans General Hospital. Primary endpoints: Maximum Tolerated Dose at 2 years and Overall Response Rate at 2 years. Started Aug 2025; status: recruiting.
02
Drugs
HCB-101
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07136545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136545.